ZNF423

Across TCGA pan-cancer cohorts, ZNF423 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ZNF423 data layer compared with 27 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ZNF423 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF423 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

OV, KICH, and LUAD are the cancer types where ZNF423 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.271	0.845	<.001	18	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
LUAD	OS	Median	II,III,IV	0.293	0.569	.010	12	view →
SCLC	OS	Median	II,III,IV	0.152	0.777	.038	6	view →
UCEC	DFS	Median	All	0.777	0.627	.034	4	view →
KIRP	DFS	Median	III,IV	0.037	0.723	<.001	3	view →
SKCM	DFS	Median	IV	1.000	0.201	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ZNF423–OV (OS)

Open the OV breakdown →